What kind of kidney injury does Belzutifan cause?

Prerenal / Hemodynamic AKI — Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

Is kidney injury from Belzutifan reversible?

Reversible. Typical onset: Anemia and hypoxia develop over the first weeks of therapy..

How should kidney function be monitored during Belzutifan therapy?

Hemoglobin at baseline and periodically (anemia is the signature toxicity); Oxygen saturation / assessment for hypoxia; Serum creatinine in patients with solitary or operated kidneys.

How can kidney injury from Belzutifan be prevented?

Erythropoiesis-stimulating agents or transfusion per anemia guidance Maintain hydration; minimize nephrotoxin/contrast exposure in reduced-nephron patients

Who is at higher risk of kidney injury from Belzutifan?

Solitary or operated kidney (reduced nephron mass); Baseline anemia or cardiopulmonary disease; Volume depletion; Concurrent nephrotoxins/contrast.

Back to explorer

Printable monograph

HIF-2α inhibitor

Belzutifan

Welireg · Belzu

HIF-2α inhibitor · approved 2021 · 7 citations

Up to date· through 2025

Fairly sourced5/9 · 5 signals

Met: 7 citations
Not met: 12+ references
Not met: Accrued over 10+ years (span: 4y)
Met: Beyond single case reports
Met: High-impact journal
Met: Landmark reference
Met: Current through 2025
Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A HIF-2α inhibitor whose on-target anemia and hypoxia define its profile — kidney injury is largely indirect.

MildHIF-2α inhibitor

VHL disease-associated RCCVHL disease-associated CNS hemangioblastomas / pancreatic NETAdvanced clear-cell RCC (previously treated)

§01

Signature kidney injury

Signature lesion

Prerenal / Hemodynamic AKI

Anemia is the most common on-target adverse event (the leading grade 3 event in pivotal trials) and hypoxia is frequent. Direct nephrotoxicity is not a prominent or well-quantified signal; renal function changes mostly reflect underlying RCC/nephrectomy status.Source: Choueiri et al., NEJM 2024 (LITESPARK-005; anemia leading G3 event)

Onset & rechallenge

Time to injurySubacute (~1–6 weeks)

Anemia and hypoxia emerge over the first weeks of therapy.

Distilled from: “Anemia and hypoxia develop over the first weeks of therapy.”

§02

Renal toxicities, ranked

This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Prerenal / Hemodynamic AKI#1 · Signaturequalitative — no citable incidence
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

§03

Kidney injury

Mechanism of kidney injury

By suppressing HIF-2α–mediated erythropoietin transcription, belzutifan causes anemia (and consequent hypoxia/fatigue). Any renal compromise is mostly indirect — hemodynamic or related to reduced oxygen delivery — rather than a defined tubular or glomerular lesion. Many patients have a solitary or operated kidney from prior RCC surgery, so any superimposed insult (anemia-related hypoperfusion, volume depletion, contrast, other nephrotoxins) has outsized impact.

Clinical presentation

Anemia, hypoxia (sometimes requiring supplemental oxygen) and fatigue dominate. Serum creatinine is usually stable; renal changes typically reflect tumor burden or post-nephrectomy reduced nephron mass rather than drug tubulotoxicity.

Management

Dose-modify or hold for severe anemia/hypoxia (from 120 mg daily); transfuse/ESA support as needed; supplemental oxygen for hypoxia. Monitor renal function closely in patients with reduced functional renal mass.Lesion-level management framework

Risk factors

Solitary or operated kidney (reduced nephron mass)
Baseline anemia or cardiopulmonary disease
Volume depletion
Concurrent nephrotoxins/contrast

Prevention

Erythropoiesis-stimulating agents or transfusion per anemia guidance
Maintain hydration; minimize nephrotoxin/contrast exposure in reduced-nephron patients

Anticancer mechanism· how it treats cancer

First-in-class oral inhibitor of hypoxia-inducible factor-2α (HIF-2α). In VHL-deficient clear-cell renal cell carcinoma (ccRCC), loss of the von Hippel-Lindau protein stabilizes HIF-2α, which drives transcription of VEGF, cyclin D1, EPO and other pro-tumor/angiogenic genes; belzutifan blocks HIF-2α from dimerizing with HIF-1β/ARNT, shutting down this program in ccRCC and VHL-disease–associated tumors.

Note · The dominant, well-characterized toxicities are anemia and hypoxia — direct on-target consequences of HIF-2α/EPO suppression — not direct nephrotoxicity. The renal profile is still emerging.

§04

Clinical depth

Renal dose adjustment

No baseline renal dose change per the FDA label, including ESKD; in severe impairment (eGFR 15-29, MDRD) the label directs monitoring for increased adverse reactions and modifying the dose accordingly. Standard 120 mg once daily; modifications are driven by anemia and hypoxia rather than CrCl.

Dialyzability & ESKD dosing

Not characterized; belzutifan is highly protein-bound and primarily metabolized by UGT2B17/CYP2C19, so it is unlikely to be substantially removed by dialysis. No ESKD dosing guidance exists.

Differential diagnosis

Distinguish anemia-driven fatigue/hypoxia (the expected on-target effect) from cardiopulmonary or hemorrhagic causes; separate a creatinine change due to reduced post-nephrectomy nephron mass or volume depletion from any true drug-related lesion (rare).

Monitoring

Hemoglobin at baseline and periodically (anemia is the signature toxicity)
Oxygen saturation / assessment for hypoxia
Serum creatinine in patients with solitary or operated kidneys

Key trials & series

Choueiri et al., NEJM 2024 — LITESPARK-005 phase 3 (belzutifan vs everolimus in advanced ccRCC; registrational; anemia leading grade 3 event)
Jonasch et al., NEJM 2021 — LITESPARK-004 (VHL-associated RCC)
Iliopoulos et al., Lancet Oncol 2024 — LITESPARK-004 VHL CNS hemangioblastomas

Clinical pearls

Belzutifan's signature toxicity is on-target anemia (suppressed EPO) — anticipate it, monitor hemoglobin, and support rather than reflexively stop the drug.
Many recipients have a single working kidney from RCC surgery, so protect renal reserve aggressively.
Hypoxia can occur even without anemia and may need supplemental oxygen; it is a mechanism-based, expected effect.

Where it strikes· nephron segments & injury signatures

Nephron segments

Vasculature / Endothelium

Glomerular & peritubular capillaries

Injury signatures

Prerenal / Hemodynamic AKI

§05

References

7 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.

Evidence accrual

7 references · 2021–2025 · 5 since 2023

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

FDA label — boxed warning & renal dosing· boxed warning · renal impairment

Quoted verbatim from this agent's current FDA label (Jun 2026) — not paraphrased or interpreted. Full label on DailyMed .

Boxed warning

WARNING: EMBRYO-FETAL TOXICITY Exposure to WELIREG during pregnancy can cause embryo-fetal harm. Verify pregnancy status prior to the initiation of WELIREG. Advise patients of these risks and the need for effective non-hormonal contraception. WELIREG can render some hormonal contraceptives ineffective [see Warnings and Precautions (5.3) , Drug Interactions (7.2) , Use in Specific Populations (8.1 , 8.3) ]. WARNING: EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. Exposure to WELIREG during pregnancy can cause embryo-fetal harm. Verify pregnancy status prior to the initiation of WELIREG. Advise patients of these risks and the need for effective non-hormonal contraception. WELIREG can render some hormonal contraceptives ineffective. ( 5.3 , 7.2 , 8.1 , 8.3 )

Renal impairment — from the label

No dosage modification of WELIREG is recommended in patients with renal impairment including end-stage renal disease. For patients with severe renal impairment (eGFR 15-29 mL/min estimated by MDRD) monitor for increased adverse reactions and modify the dosage as recommended [see Dosage and Administration (2.2) , Clinical Pharmacology (12.3) ].

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 1,573 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.

FAERS reported renal phenotypes· 3 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-10-01.

What reporting says about this profile's documented lesions

Prerenal / Hemodynamic AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.

Glomerular Injury / Proteinuria

ROR 5.0795% CI 2.80–9.17· 11 reports

SIADH / Hyponatremia

ROR 3.1795% CI 2.02–4.99· 19 reports

Electrolyte Disturbance

ROR 2.6995% CI 1.95–3.71· 38 reports

FAERS outcomes & reporting trend· 9.5% of reports w/ death · 43.1% w/ hospitalization

9.5%

Reported with a death outcome

150 of 1,573 reports

43.1%

Reported with hospitalization

678 of 1,573 reports

Reports per year

Yearly FAERS report volume · most recent year is partial.

FAERS adverse-event signal — all organ systems· 9 systems · 1,573 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-10-01.

Disproportionality (acute kidney injury):ROR 1.4995% CI 0.93–2.41· 17 AKI reports ·no disproportionate AKI reporting signal (CI spans 1).

Blood & lymphatic

Anaemia283Haemoglobin Decreased59Platelet Count Decreased27

Respiratory

Hypoxia146Dyspnoea63Oxygen Saturation Decreased47

General / constitutional

Fatigue121Asthenia32Malaise32Fall24

Gastrointestinal

Diarrhoea61Nausea42Vomiting26

Nervous system

Dizziness31Headache27

Immune / infection

Pneumonia36

Cardiac

Cardiac Failure30

Metabolic & electrolyte

Decreased Appetite26

Vascular

Hypertension26

Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Belzutifan sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Dordaviprone

Modeyso · Imipridone (ONC201; DRD2/ClpP)

Profile

2025 imipridone for H3 K27M glioma; renally well tolerated — QT prolongation, not nephrotoxicity, is the safety focus.

PRE

Mild#1 · 97% phenotype match

Iberdomide

Zenbexus · Cereblon E3 ligase modulator (CELMoD)

Profile

2026 first-in-class CELMoD; no attributable lesion (renal impairment 11% vs 8% on the comparator arm) but exposure rises 1.8x below eGFR 30 off dialysis.

PRE

Mild#2 · 97% phenotype match

Casdatifan

HIF-2α inhibitor (investigational)

Profile

Trial-stage RCC HIF-2α inhibitor; renal profile being defined.

PRE

Mild#3 · 97% phenotype match

Denileukin diftitox

Lymphir · Immunotoxin (IL-2–diphtheria)

Profile

Capillary-leak syndrome → prerenal AKI.

PRE

Moderate#4 · 91% phenotype match

Asparaginase

Elspar · Enzyme

Profile

Rare AKI; pancreatitis-mediated.

PRE

Mild#5 · 89% phenotype match

Dacarbazine

DTIC · Alkylator

Profile

Rare hepatic veno-occlusive disease; minimal direct renal injury.

PRE

Mild#6 · 89% phenotype match

Compare Belzutifan with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Other targeted agents

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.